-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the beginning of the new year of 2023, the pharmaceutical industry has ushered in a number of heavy policies
.
The front foot of the national talk ended, followed by the collection of dental implants
.
Subsequently, the eighth batch of centralized procurement in the country also came with news
.
On January 10, a notice on submitting procurement data related to the scope of the eighth batch of centralized procurement of drugs organized by the state was circulated in the industry
.
The catalogue of varieties at the end of the document basically confirms the conjecture in the industry: the eighth batch of national procurement is still dominated by chemical drugs
.
Traditional Chinese medicine and biological drugs are temporarily safe
.
in the industry.
The eighth batch of national procurement is still dominated by chemical drugs
.
Data source: NMPA, CPM Medical Institute database
At present, the centralized procurement of proprietary Chinese medicines is mainly in the form of inter-provincial alliances, and biological drugs are only carried out
in a few provinces and cities except for the sixth batch of national procurement.
Compared with the past, the number of varieties included in the eighth batch of national procurement is small
.
A total of 41 generic names and 181 specifications are involved, covering areas such as antibiotics, hypertension drugs, anesthetic drugs, antidepressants, antiepileptic drugs, etc
.
The eighth batch of centralized procurement also continued the previous characteristics, and injection became the main dosage form of centralized procurement, with a total of 17 types
.
.
Antibiotics, hypertension drugs, anesthetic drugs, antidepressants, antiepileptic drugs, etc
It is worth noting that although the number of varieties in the eighth batch is not as good as before, the number of enterprises competing under the same variety is more
.
After combing the Knowledge, the Health Bureau found that the eighth batch of varieties, the number of domestic evaluated enterprises are more than
4.
Some varieties are quite competitive, such as cefoxitin for injection, sodium valproate injection, ornidazole injection, etc.
, the number of domestic evaluation enterprises are more than
10.
10 domestic enterprises that have been evaluated for injection, such as cefoxitin, valproate injection, and ornidazole injection.
In addition, the eighth batch of centralized procurement will also usher in the competition
of original research manufacturers of foreign enterprises.
According to the statistics of the Health Bureau, at least 26 varieties have been approved by foreign companies in China, such as Pfizer, Sanofi, Merck Sharp & Dohme, AstraZeneca, etc
.
.
Online documents show that the reporting of medical institutions in various provinces will be officially launched on January 13, and the review of drug procurement demand will be completed by February 21
.
According to the collective procurement time of the past few batches, it will begin to land in various provinces and cities in about four or five months
.
Antibiotics are basically fully covered by national centralized procurement
Antibiotics are basically fully covered by national centralized procurementThe field of anti-infection has always been the focus of
national centralized procurement.
In the online documents, cephalosporin antimicrobials, which occupy the main market share, are still important varieties
.
Previously, 16 varieties of cephalosporin antimicrobials have been included in the national collection
.
The eighth batch of collective procurement documents that came out this time showed that cefdinil granules, cefoperazone sulbactam sodium, cefotaxime sodium, cefoxitin sodium, and cefodizime sodium for injection were all selected
.
At this point, the large varieties of cephalosporins have basically entered the national collection
.
.
According to data from Minai.
com, among cephalosporin antibacterial drugs, cefoperazone sulbactam injection is the "top stream", with terminal sales of nearly 7 billion yuan in China's public medical institutions, and the sales of cefdinil granules are behind, less than 100 million yuan
.
Cefoperazone sodium sulbactam sodium is a compound preparation of cefoperazone sodium and sulbactam sodium, which is the first-line drug of clinical anti-infective drugs at present, and a total of 11 specifications are involved in the eighth batch of collection
.
The product has formed a unique situation in Pfizer in China - the product was approved on May 12, 2020, and by the first half of 2022, the market share exceeded 80%.
In fact, for this popular variety, domestic companies are also piling up production
.
A search on the website of the State Food and Drug Administration found that cefoperazone sulbactam injection for injection involved more than
80 enterprises.
According to the collective procurement rules, enterprises that fail to pass the consistency evaluation will be removed from the network
.
According to the database of CPM Medical Institute, only 7 domestic manufacturers have passed the consistency evaluation, including Runze Pharmaceutical, Chengdu Beite Pharmaceutical, Qilu Pharmaceutical, Hainan Herui Pharmaceutical, etc
.
.
Piracillin, tazobactam is another large variety
of anti-infection.
Data show that in 2019, the sales of this product in China's public hospital terminals reached 8 billion yuan
.
It is worth noting that North China Pharmaceutical is the first company
to pass the consistency evaluation.
But Qilu Pharmaceutical's presence is stronger
.
According to public information, Qilu, which is mainly based on anti-infection product lines, is the world's largest manufacturer of raw materials and preparations for piperacillin tazobactam, and its price is only 1/3
of the original drug.
of the original drug.
Judging from the circulation documents, Qilu has 5 varieties that can be selected
in the eighth batch of national mining.
If the national procurement is won, Qilu's share in the anti-infection market will be further expanded
.
.
It is worth noting that coupled with the catalogue circulated this time, large varieties of antibiotics have been basically fully covered
by the national centralized procurement.
Under the influence of centralized procurement, the space for gold sales has shrunk significantly, and the terminal antibiotic abuse situation in hospitals is likely to change
accordingly.
accordingly.
Injections are the focus of centralized procurement, and anesthesia drugs are also in the catalog
Injections are the focus of centralized procurement, and anesthesia drugs are also in the catalogSince the fifth batch, the national centralized procurement has been tilted towards injections, and by the eighth batch, injections have become the focus of
centralized procurement.
According to online documents, there are 17 varieties of injections, accounting for 41% of the total number of varieties, which is basically the same
as the previous level.
Under centralized procurement, clinical drug use is likely to usher in a major reshuffle
.
.
Anesthesia drugs and somatostatin are also common clinical varieties
.
However, in the eighth batch of centralized procurement catalogue on the Internet, there is only one anesthetic - levobupivacaine
.
.
At present, the domestic anesthetic drug market is basically occupied by Renfu, Hengrui and Jiangsu Enhua, with a market share of 52.
98%
in 2021.
According to the State Food and Drug Administration, the current layout of levobupivacaine, in addition to Renfu and Hengrui, there are 4 enterprises
such as Ruiyang Pharmaceutical and Zhuhai Rundu.
Renfu completed the consistency evaluation as early as 2020, and Hengrui was two years late, and only passed it
in April last year.
There is no doubt that the eighth batch of national procurement has reached a critical moment
for the two giants to seize the market.
such as Ruiyang Pharmaceutical and Zhuhai Rundu.
The eighth batch of national procurement has reached a critical moment
for the two giants to seize the market.
As a classic old drug, somatostatin was also selected for national procurement
this time.
this time.
According to data from Minai.
com, the sales of terminal somatostatin for injection in China's public medical institutions exceeded 2.
4 billion yuan in 2020, with a year-on-year increase of 2.
46%
in the first half of 2021.
At present, there are many
domestic manufacturers of somatostatin.
Somatostatin was developed and produced by Merck, approved to enter China in 2001, and Hainan Zhonghe Pharmaceutical completed its first imitation
in 2003.
According to statistics, there are 16 domestic manufacturers of somatostatin, and a total of 7 have been evaluated
.
From the perspective of the overall competition pattern, the original research company Merck dominates, with a domestic market share of somatostatin of 35.
52% in 2021, followed by Jiangsu Coast and Shenzhen Hanyu.
52% in 2021, followed by Jiangsu Coast and Shenzhen Hannyu
.
Previously, the alliance of four provinces of Zhejiang, Gansu, Guangdong and Yu'e had carried out centralized procurement of somatostatin, Zhejiang centralized procurement of Zhonghainan Shuangcheng Pharmaceutical and Beijing Shuanglu Pharmaceutical were selected, and Shanghai Huayuan Pharmaceutical was selected
by the alliance of four provinces.
These three companies do not have a high market share, and small enterprises are also expected to break through from centralized procurement
.
According to data from Minai.
com, the total sales of the eighth batch of nationally harvested varieties in China's public medical institutions exceeded 60 billion yuan in 2021, and many of the enterprises involved were well-known listed companies at home and abroad, such as CSPC Pharmaceutical Group, Beite Pharmaceutical, Qilu Pharmaceutical, Chia Tai Tianqing, Kelun Pharmaceutical, etc
.
Among them, Beite Pharmaceutical, CSPC Pharmaceutical Group, Yangzijiang Pharmaceutical, etc.
have 5 or more
evaluated varieties.
have 5 or more
evaluated varieties.
